Bipartite network analysis reveals metabolic gene expression profiles that are highly associated with the clinical outcomes of acute myeloid leukemia
Authors: 
Fanfan Xie, Mingxiong He, Li He, Keqin Liu, Menglong Li, Guoquan Hu, Zhining WenAuthors Info & Claims
Pages 150 - 157
Abstract
Display Omitted Metabolic genes are as important prognostic biomarkers as oncogenes.We found that significant differences exist in metabolic processes of AML patients.We identified 62 metabolic genes that highly associated with the prognosis of AML.Genes ALAS2, BCAT1, BLVRB and HK3 were distinctly expressed in the AML patients. Dysregulated and reprogrammed metabolism are one of the most important characteristics of cancer, and exploiting cancer cell metabolism can aid in understanding the diverse clinical outcomes for patients. To investigate the differences in metabolic pathways among patients with acute myeloid leukemia (AML) and differential survival outcomes, we systematically conducted microarray data analysis of the metabolic gene expression profiles from 384 patients available from the Gene Expression Omnibus and Cancer Genome Atlas databases. Pathway enrichment analysis of differentially expressed genes (DEGs) showed that the metabolic differences between low-risk and high-risk patients mainly existed in two pathways: biosynthesis of unsaturated fatty acids and oxidative phosphorylation. Using the gene-pathway bipartite network, 62 metabolic genes were identified from 272 DEGs involved in 88 metabolic pathways. Based on the expression patterns of the 62 genes, patients with shorter overall survival (OS) durations in the training set (hazard ratio (HR)=1.58, p=0.038) and in two test sets (HR=1.69 and 1.56 and p=0.089 and 0.029, respectively) were well discriminated by hierarchical clustering analysis. Notably, the expression profiles of ALAS2, BCAT1, BLVRB, and HK3 showed distinct differences between the low-risk and high-risk patients. In addition, models for predicting the OS outcome of AML from the 62 gene signatures achieved improved performance compared with previous studies. In conclusion, our findings reveal significant differences in metabolic processes of patients with AML with diverse survival durations and provide valuable information for clinical translation.
References
[1]
L.K. Boroughs, R.J. DeBerardinis, Metabolic pathways promoting cancer cell survival and growth, Nat. Cell Biol., 17 (2015) 351-359.
[2]
Cancer Genome Atlas Research Network, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia, N. Engl. J. Med., 368 (2013) 2059-2074.
[3]
C.C. Chang, C.J. Lin, LIBSVM: a library for support vector machines, ACM Trans. Intell. Syst. Technol., 2 (2011) 27.
[4]
L. Chen, J. Xuan, R.B. Riggins, R. Clarke, Y. Wang, Identifying cancer biomarkers by network-constrained support vector machines, BMC Syst. Biol., 5 (2011) 161.
[5]
R.J. Deberardinis, N. Sayed, D. Ditsworth, C.B. Thompson, Brick by brick: metabolism and tumor cell growth, Curr. Opin. Genet. Dev., 18 (2008) 54-61.
[6]
Y. Fang, L.N. Xie, X.M. Liu, Z. Yu, F.S. Kong, N.X. Song, Dysregulated module approach identifies disrupted genes and pathways associated with acute myelocytic leukemia, Eur. Rev. Med. Pharmacol. Sci., 19 (2015) 4811-4826.
[7]
E.A. Federzoni, M. Humbert, B.E. Torbett, G. Behre, M.F. Fey, M.P. Tschan, CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation, Sci. Rep., 4 (2014) 4261.
[8]
P. Ghaffari, A. Mardinoglu, A. Asplund, S. Shoaie, C. Kampf, M. Uhlen, Identifying anti-growth factors for human cancer cell lines through genome-scale metabolic modeling, Sci. Rep., 5 (2015) 8183.
[9]
L. He, Y. Wang, Y. Yang, L. Huang, Z. Wen, Identifying the gene signatures from gene-pathway bipartite network guarantees the robust model performance on predicting the cancer prognosis, Biomed. Res. Int., 2014 (2014) 424509.
[10]
K.R. Hess, K. Anderson, W.F. Symmans, V. Valero, N. Ibrahim, J.A. Mejia, Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer, J. Clin. Oncol., 24 (2006) 4236-4244.
[11]
P. Holme, F. Liljeros, C.R. Edling, B.J. Kim, Network bipartivity, Phys. Rev. E Stat. Nonlinear Soft Matter Phys., 68 (2003) 056107.
[12]
P.P. Hsu, D.M. Sabatini, Cancer cell metabolism: warburg and beyond, Cell, 134 (2008) 703-707.
[13]
J. Hu, J.W. Locasale, J.H. Bielas, J. OSullivan, K. Sheahan, L.C. Cantley, Heterogeneity of tumor-induced gene expression changes in the human metabolic network, Nat. Biotechnol., 31 (2013) 522-529.
[14]
M. Jang, S.S. Kim, J. Lee, Cancer cell metabolism: implications for therapeutic targets, Exp. Mol. Med., 45 (2013) e45.
[15]
L. Jiang, L. Huang, Q. Kuang, J. Zhang, M. Li, Z. Wen, Improving the prediction of chemotherapeutic sensitivity of tumors in breast cancer via optimizing the selection of candidate genes, Comput. Biol. Chem., 49 (2014) 71-78.
[16]
W.H. Koppenol, P.L. Bounds, C.V. Dang, Otto Warburgs contributions to current concepts of cancer metabolism, Nat. Rev. Cancer, 11 (2011) 325-337.
[17]
Y. Lee, A.C. Scheck, T.F. Cloughesy, A. Lai, J. Dong, H.K. Farooqi, Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age, BMC Med. Genomics, 1 (2008) 52.
[18]
MAQC Consortium, L. Shi, L.H. Reid, W.D. Jones, R. Shippy, J.A. Warrington, The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements, Nat. Biotechnol., 24 (2006) 1151-1161.
[19]
K.H. Metzeler, M. Hummel, C.D. Bloomfield, K. Spiekermann, J. Braess, M.C. Sauerland, An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia, Blood, 112 (2008) 4193-4201.
[20]
Y. Moreau, L.C. Tranchevent, Computational tools for prioritizing candidate genes: boosting disease gene discovery, Nat. Rev. Genet., 13 (2012) 523-536.
[21]
S.N. Ononye, W. Shi, V.B. Wali, B. Aktas, T. Jiang, C. Hatzis, Metabolic isoenzyme shifts in cancer as potential novel therapeutic targets, Breast Cancer Res. Treat., 148 (2014) 477-488.
[22]
A. Patsialou, Y. Wang, J. Lin, K. Whitney, S. Goswami, P.A. Kenny, Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients, Breast Cancer Res., 14 (2012) R139.
[23]
H.S. Phillips, S. Kharbanda, R. Chen, W.F. Forrest, R.H. Soriano, T.D. Wu, Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis, Cancer Cell, 9 (2006) 157-173.
[24]
S.S. Pinho, C.A. Reis, Glycosylation in cancer: mechanisms and clinical implications, Nat. Rev. Cancer, 15 (2015) 540-555.
[25]
J. Roy, C. Winter, Z. Isik, M. Schroeder, Network information improves cancer outcome prediction, Brief. Bioinf., 15 (2014) 612-625.
[26]
A. Ruiz-Vela, C. Aguilar-Gallardo, A.M. Martnez-Arroyo, M. Soriano-Navarro, V. Ruiz, C. Simn, Specific unsaturated fatty acids enforce the transdifferentiation of human cancer cells toward adipocyte-like cells, Stem Cell Rev., 7 (2011) 898-909.
[27]
J.D. Shaughnessy, F. Zhan, B.E. Burington, Y. Huang, S. Colla, I. Hanamura, A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1, Blood, 109 (2007) 2276-2284.
[28]
R.J. Shaw, Glucose metabolism and cancer, Curr. Opin. Cell Biol., 18 (2006) 598-608.
[29]
L. Shi, G. Campbell, W.D. Jones, F. Campagne, Z. Wen, S.J. Walker, The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models, Nat. Biotechnol., 28 (2010) 827-838.
[30]
G. Solaini, G. Sgarbi, A. Baracca, Oxidative phosphorylation in cancer cells, Biochim. Biophys. Acta, 1807 (2011) 534-542.
[31]
C. Staiger, S. Cadot, R. Kooter, M. Dittrich, T. Mller, G.W. Klau, A critical evaluation of network and pathway-based classifiers for outcome prediction in breast cancer, PLoS One, 7 (2012) e34796.
[32]
M. Tnjes, S. Barbus, Y.J. Park, W. Wang, M. Schlotter, A.M. Lindroth, BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1, Nat. Med., 19 (2013) 901-908.
[33]
J. Tan, C.Y. Yu, Z.H. Wang, H.Y. Chen, J. Guan, Y.X. Chen, Genetic variants in the inositol phosphate metabolism pathway and risk of different types of cancer, Sci. Rep., 5 (2015) 8473.
[34]
L.J. vant Veer, H. Dai, M.J. van de Vijver, Y.D. He, A.A. Hart, M. Mao, Gene expression profiling predicts clinical outcome of breast cancer, Nature, 415 (2002) 530-536.
[35]
M.G. Vander Heiden, L.C. Cantley, C.B. Thompson, Understanding the Warburg effect: the metabolic requirements of cell proliferation, Science, 324 (2009) 1029-1033.
[36]
M.G. Vander Heiden, Targeting cancer metabolism: a therapeutic window opens, Nat. Rev. Drug Discov., 10 (2011) 671-684.
[37]
M.G. Vander Heiden, Exploiting tumor metabolism: challenges for clinical translation, J. Clin. Invest., 123 (2013) 3648-3651.
[38]
V.N. Vapnik, The Nature of Statistical Learning Theory, Springer Press, 1995.
[39]
V.N. Vapnik, Statistical Learning Theory, Wiley Press, 1998.
[40]
H.J. Wang, L.Q. Huang, R.Y. Jing, Y.N. Yang, K.Q. Liu, M.L. Li, Identifying oncogenes as features for clinical cancer prognosis by Bayesian nonparametric variable selection algorithm, Chemometr. Intell. Lab. Syst., 146 (2015) 464-471.
[41]
O. Warburg, K. Posener, E. Negelein, On the metabolism of tumors, Biochem. Z., 152 (1924) 309-344.
[42]
J. Xu, R. Jing, Y. Liu, A new strategy for exploring the hierarchical structure of cancers by adaptively partitioning functional modules from gene expression network, Sci. Rep., 6 (2016) 28720.
[43]
F. Zhan, J. Hardin, B. Kordsmeier, K. Bumm, M. Zheng, E. Tian, Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells, Blood, 99 (2002) 1745-1757.
[44]
Y. Zhao, E.B. Butler, M. Tan, Targeting cellular metabolism to improve cancer therapeutics, Cell. Death Dis., 4 (2013) e532.
[45]
T. Zhou, J. Ren, M. Medo, Y.C. Zhang, Bipartite network projection and personal recommendation, Phys. Rev. E Stat. Nonlinear Soft Matter Phys., 76 (2007) 046115.
[46]
W. Zhou, X. Feng, H. Li, L. Wang, H. Li, B. Zhu, Functional evidence for a nasopharyngeal carcinoma-related gene BCAT1 located at 12p12, Oncol. Res., 16 (2007) 405-413.
[47]
W. Zhou, X. Feng, C. Ren, X. Jiang, W. Liu, W. Huang, Over-expression of BCAT1, a c-Myc target gene, induces cell proliferation, migration and invasion in nasopharyngeal carcinoma, Mol. Cancer, 12 (2013) 53.
- Bipartite network analysis reveals metabolic gene expression profiles that are highly associated with the clinical outcomes of acute myeloid leukemia
Recommendations
High expression of APOBEC3G predicts unfavorable prognosis and immune infiltration in patients with acute myeloid leukemia
ICBBT '23: Proceedings of the 2023 15th International Conference on Bioinformatics and Biomedical TechnologyThe potential clinical benefits of immunotherapy against acute myeloid leukemia (AML) have been suggested recently. Thus, identifying the molecular mechanisms underlying immune surveillance evasion is critical. The APOBEC family (apolipoprotein B mRNA ...
Prognostic Significance and Functional Implications of PPP1R12B in Acute Myeloid Leukemia
ICBBT '24: Proceedings of the 2024 16th International Conference on Bioinformatics and Biomedical TechnologyAcute Myeloid Leukemia (AML) is a life-threatening hematologic malignancy characterized by rapid proliferation of abnormal myeloid cells. This study employs comprehensive bioinformatics analyses to elucidate the role of the PPP1R12B gene, a member of the ...
Deep learning in molecular biology marker recognition of patients with acute myeloid leukemia
AbstractIn this study, the deep belief network (DBN) algorithm was used to identify the Wilm’s tumor 1 (WT1) gene expression levels, and then, the role of WT1 expression in the classification of acute myeloid leukemia (AML) was explored. 121 AML patients ...
Comments
Please enable JavaScript to view thecomments powered by Disqus.Information & Contributors
Information
Published In
Copyright © Elsevier Ltd.
Publisher
Elsevier Science Publishers B. V.
Netherlands
Publication History
Published: 01 April 2017
Author Tags
Qualifiers
- Research-article
Contributors
Other Metrics
Bibliometrics & Citations
Bibliometrics
Article Metrics
- 0Total Citations
- 0Total Downloads
- Downloads (Last 12 months)0
- Downloads (Last 6 weeks)0
Reflects downloads up to 24 Dec 2024